A Phase II Study of STSP-0902 Ophthalmic Solution in Patients With Neurotrophic Keratitis

PHASE2RecruitingINTERVENTIONAL

Enrollment

Participants

Timeline

Start Date

June 12, 2025

Primary Completion Date

April 30, 2026

Study Completion Date

April 30, 2026

Conditions

Neurotrophic Keratitis

Interventions

DRUG

STSP-0902 ophthalmic solution

Eye drop, 3 times daily for 8 weeks

DRUG

STSP-0902 ophthalmic solution

Eye drop, 6 times daily for 8 weeks

DRUG

STSP-0902 Placebo

Eye drop, 3 or 6 times daily for 8 weeks

Trial Locations (1)

RECRUITING

Shandong First Medical University Affiliated Eye Hospital, Jinan

All Listed Sponsors

lead

Staidson (Beijing) Biopharmaceuticals Co., Ltd

INDUSTRY

NCT06975748 - A Phase II Study of STSP-0902 Ophthalmic Solution in Patients With Neurotrophic Keratitis | Biotech Hunter | Biotech Hunter